United States

Athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases. We are engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. Through the application of our proprietary technologies, we have established a pipeline of therapeutic product development programs in multiple disease areas. This pipeline includes both stem cell therapy and pharmaceuticals.

Cardiovascular Diseases

Central Nervous System (CNS)

Lung Diseases

Athersys Inc.

Ischemic stroke

MultiStem cells act in several ways to rebalance the immune system. Our data suggests that administering MultiStem cells results in less inflammation, less activation and migration of the peripheral immune system to the site of injury. In essence, the “bad cells” are “turned off” while at the same time, the “good cells” are “turned on”. MultiStem has shown to decrease the adverse results of inflammation, while activating reparative immune cells.
Biomarker analysis shows that inflammatory cytokine levels (molecules associated with immune cell signaling) decrease in the presence of MultiStem cells.
<a href="https://www.athersys.com/multistem-therapy/mechanisms-of-action/default.aspx">Source</a>

MultiStem

Trauma

MultiStem 

Acute respiratory distress syndrome

COVID-19

MultiStem®, is a patented, adult-derived "off-the-shelf" stem cell therapy platform; cells act in several ways to rebalance the immune system. Our data suggests that administering MultiStem cells results in less inflammation, less activation and migration of the peripheral immune system to the site of injury. In essence, the “bad cells” are “turned off” while at the same time, the “good cells” are “turned on”. MultiStem has shown to decrease the adverse results of inflammation, while activating reparative immune cells.
Biomarker analysis shows that inflammatory cytokine levels (molecules associated with immune cell signaling) decrease in the presence of MultiStem cells, making it a possible COVID therapy.
<a href="https://www.athersys.com/multistem-therapy/mechanisms-of-action/default.aspx">Source</a>

Athersys Inc.

Company Details